Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Grebely

Showing results (91-100 of 368) with videos related to

Pageof 37
Sort By:
Journal of Hepatology|July 13, 2016
Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based studyMaryam Alavi, Matthew G Law, Jason Grebely, et al.
American Journal of Public Health|November 15, 2019
Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in CanadaBrendan Jacka, Sarah Larney, Louisa Degenhardt, et al.
Drug and Alcohol Review|March 24, 2021
Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, AustraliaDaisy Gibbs, Jason Grebely, Rachel Sutherland, et al.
Journal of Hepatology|August 14, 2017
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regressionReem Waziry, Behzad Hajarizadeh, Jason Grebely, et al.
Journal of Viral Hepatitis|September 12, 2025
Policymaker Perspectives on the Role of Health Systems in Sustainable Hepatitis C Point-Of-Care Testing in AustraliaAnna Conway, Jason Grebely, Carla Treloar, et al.
Drug and Alcohol Review|January 5, 2023
Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: An ecological analysisAnjalee Syangbo, Matthew Hickman, Samantha Colledge-Frisby, et al.
The International Journal on Drug Policy|May 20, 2025
Implications of the fragility of opioid agonist treatment continuity on hepatitis C re-exposure concerns among people in prison: a qualitative studyLise Lafferty, Tracey Brown, Colette McGrath, et al.
Hepatology (Baltimore, Md.)|April 10, 2014
Genetics of spontaneous clearance of hepatitis C virus infection: a complex topic with much to learnJason Grebely, Gregory J Dore, Arthur Y Kim, et al.
Drug and Alcohol Dependence|January 13, 2015
Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: a 15-year observational cohort studySarah Larney, Jason Grebely, Michael Falster, et al.
The International Journal on Drug Policy|February 1, 2025
Acceptability of hepatitis C testing using point-of-care testing and dried blood spot collection among people at risk of hepatitis C infectionAnnabelle Stevens, Lise Lafferty, Carla Treloar, et al.
Pageof 37

Showing results (91-100 of 368) with videos related to

Sort By:
Pageof 37
Journal of Hepatology|July 13, 2016
Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based studyMaryam Alavi, Matthew G Law, Jason Grebely, et al.
American Journal of Public Health|November 15, 2019
Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in CanadaBrendan Jacka, Sarah Larney, Louisa Degenhardt, et al.
Drug and Alcohol Review|March 24, 2021
Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, AustraliaDaisy Gibbs, Jason Grebely, Rachel Sutherland, et al.
Journal of Hepatology|August 14, 2017
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regressionReem Waziry, Behzad Hajarizadeh, Jason Grebely, et al.
Journal of Viral Hepatitis|September 12, 2025
Policymaker Perspectives on the Role of Health Systems in Sustainable Hepatitis C Point-Of-Care Testing in AustraliaAnna Conway, Jason Grebely, Carla Treloar, et al.
Drug and Alcohol Review|January 5, 2023
Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: An ecological analysisAnjalee Syangbo, Matthew Hickman, Samantha Colledge-Frisby, et al.
The International Journal on Drug Policy|May 20, 2025
Implications of the fragility of opioid agonist treatment continuity on hepatitis C re-exposure concerns among people in prison: a qualitative studyLise Lafferty, Tracey Brown, Colette McGrath, et al.
Hepatology (Baltimore, Md.)|April 10, 2014
Genetics of spontaneous clearance of hepatitis C virus infection: a complex topic with much to learnJason Grebely, Gregory J Dore, Arthur Y Kim, et al.
Drug and Alcohol Dependence|January 13, 2015
Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: a 15-year observational cohort studySarah Larney, Jason Grebely, Michael Falster, et al.
The International Journal on Drug Policy|February 1, 2025
Acceptability of hepatitis C testing using point-of-care testing and dried blood spot collection among people at risk of hepatitis C infectionAnnabelle Stevens, Lise Lafferty, Carla Treloar, et al.
Pageof 37